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Abstract
Aim: External quality assurance (EQA) is an extremely valuable resource for clinical pathologists
to maintain high standards, improve diagnostic skills, and possibly revalidate medical license. The
aim of this study was to participate in and compare four international slide survey programs (UK,
IAP-Germany, USA-Canada, Australasia) in pediatric histopathology for clinical pathologists with
the aim to use it as a revalidation method.
Methods: The following parameters were evaluated: number of circulations per year, number of
slides, membership requirement, proof of significant pediatric pathology work, open to overseas
participants, laboratory accreditation, issue of continuing professional development certificates and
credits, slides discussion meeting, use of digital images, substandard performance letter, and
anonymity of responses.
Results: The UK scheme, which has sampling procedure over several time frames (2 circulations/
year, 30 slides), partial confidentiality, and multiple sources of data and assessors, can be used as a
model for revalidation. The US-Canadian and Australasian schemes only partially fulfill the
revalidation requirements. The IAP scheme appears to be essentially an educational program and
may be unsuitable for revalidation.
Conclusion: The purposes and programs of EQA schemes vary worldwide. In order for it to be
used for revalidation, it is advisable that EQA schemes are immediately unified.
Background
Clinical Governance is a term, originally used in the
National Health Service (NHS) of the United Kingdom
(UK), to describe a systematic approach to maintain and
improve the quality of patient care. It constitutes an offi-
cial framework through which the NHS is accountable for
the ongoing improvement of service quality safeguarding
high standards of care and creating an environment
focused on clinical excellence. Where communication
failure is the most likely cause for medical errors, the
decrease of professional skills may contribute to fatalities.
Indeed, medical errors are not usually the result of the fail-
ure of particular providers, but are often systems-related
and not attributable to individual negligence or miscon-
duct.
Pediatric Pathology embraces two areas of pathology: 1.
Specialist organ and system pathology, notably the study
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of surgical and oncological diseases, but also including
the causes, nature and processes of disease and other
forms of illness or abnormal conditions of the fetus, new-
born, infant and child; and 2. Post mortem examination
of the fetus, newborn, infant, and child [1]. Pediatric clin-
ical services rely on safe pediatric pathology services and
several initiatives can be employed to keep high the stand-
ards of care. In 1999, Quality System Essentials were intro-
duced to laboratory practice by the National Committee
for Clinical Laboratory Standards (now Clinical Labora-
tory Standards Institute [CLSI]) identifying 10 or more
major laboratory activities that are important compo-
nents of a laboratory quality program [2,3]. The essentials
include equipment, process improvement, safety and per-
sonnel development among others. All of these essentials
were developed to ensure that data reported from the lab-
oratory are as accurate as possible and serve the needs of
patients and clinicians. An important component in the
control of any laboratory procedure is the participation in
an external quality assurance (EQA) or proficiency testing
program to demonstrate that the method will give the cor-
rect result with an unknown random specimen. However,
quality assurance in a clinical laboratory also depends on
'safe' pathologists. Thus, EQA may be a fundamental part
of the continuing professional development (CPD) of
health care professionals [4]. This aspect is recognized
internationally and there is a move from continuing med-
ical education (or clinical update) to continuing profes-
sional development, including medical, managerial,
social, and personal skills.
New compulsory policies for re-validation of doctors in
specific areas are currently topical worldwide [5]. If
appraisal is a formative and developmental process
intended to identify development needs and not perform-
ance management, then revalidation is undeniably an epi-
sodic process to show capability to practise to the
professional regulator (e.g. the General Medical Council
in the UK). Thus, revalidation is an assessment that
requires a summative judgment (pass or fail). Postgradu-
ate assessment validates doctors for specialist practice ini-
tially by allowing them to be entered onto the specialist
register, whilst revalidation is the affirmation of continu-
ing fitness to practise and therefore must relate to compli-
ance with defined competencies. The usual academic
criteria for such an assessment process include: clear-cut
standards, the possible involvement of the public in judg-
ing assessments, the use of multiple sources of data and
assessors, and sampling procedures carried out over sev-
eral time frames rather than at a single point [6].
The aim of EQA in pathology is to maintain good running
standard operating procedures and to improve the per-
formance of all sub-specialties in order to ensure that
patients have access to a high quality service wherever they
live. In some countries, laboratories must provide docu-
mentation of success in EQA to maintain accreditation or
licensure and a number of programs have been developed
with assistance from professional bodies together with
significant input from accreditation agencies and institu-
tions for improving medical activities [7,8]. In this study,
we compare four slide survey programs from four geo-
graphical regions (UK, Germany, USA-Canada, and Aus-
tralasia) with regard to EQA in pathology for pediatric
pathologists in the setting of professional development.
We discuss the possibility of using these surveys as a
method for medical licensure revalidation.
Methods
Four international tissue slide survey programs the British
Paediatric Pathology Association (BRIPPA) from the UK
http://www.cardiff.ac.uk/medic/aboutus/departments/
pathology/index.html, the Royal College of Australasian
Pathologists from Australia and South-East Asia – quality
assurance programs (RCPA AP QAP) http://
www.rcpaqap.com.au/, the North-American Society of
Pediatric Pathology (SPP) including US and Canadian
subgroups http://www.spponline.org/, and the Interna-
tional Academy of Pathology (IAP) – German Division
including German speaking countries – Germany, Swit-
zerland, Austria, Lichtenstein, Luxembourg and South-
Tyrolean region of North-Italy) http://www.iap-bonn.de/
were used in this study. To take into account the different
objectives and context of each scheme we evaluated the
different EQA programs using the following parameters:
circulations per year, number of slides per year, require-
ment of membership to the regulatory body organizing
the EQA, proof of significant pediatric pathology work,
open to overseas participants, Clinical Pathology Accredi-
tation Ltd. (CPA) accreditation in the UK or similar
accreditation bodies in other countries, issue of CME cer-
tificates and CPD or continuing medical evaluation
(CME) credits, forthcoming meetings for slides discus-
sion, fixed organizer, annual report issue, improvement
changes meeting discussion, digital images option, sub-
standard performance letter, minimum levels of participa-
tion, and coding preserving the anonymity of participants.
In addition, we also evaluated the participant's option to
decide whether some cases are inappropriate for EQA pur-
poses, that some cases require expert opinion or there is
either insufficient information or poor quality staining of
the glass slides. To assess an EQA program as a revalida-
tion method we studied these surveys from the viewpoint
of clear-cut standards, the possible involvement of the
public in judging assessments (confidentiality), the use of
multiple sources of data and assessors (personal participa-
tion), and type of sampling procedures (number of circu-
lations, number of slides per year).BMC Clinical Pathology 2008, 8:11 http://www.biomedcentral.com/1472-6890/8/11
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Results
The EQA scheme for BRIPPA has full CPA accreditation,
although re-accreditation according to new standards is
due [9]. The last two circulations, i.e. circulation W and
circulation X, registered 51 and 52 participants, respec-
tively. The percentage of response was 68.2% for circula-
tion W and 78.8% for circulation X. The Pediatric
Histopathology EQA Scheme aims to provide a platform
suitable for both pediatric/perinatal pathologists and gen-
eral pathologists with responsibilities for pediatric pathol-
ogy. In the UK scheme there is a full range of pediatric
surgical material, autopsy material, and placenta. There
are two circulations per year in March and October. It is
regularly emphasized that the cases are intended to reflect
routine practice as far as is possible within the constraints
of an EQA scheme. The UK scheme is run by the BRIPPA
Committee, who supports the organizer, and is subject to
scrutiny by the Royal College of Pathologists EQA Steering
Committee and by the National Quality Assurance Advi-
sory Panel (NQAAP) on Histopathology. The participa-
tion is voluntary and the scheme is open to both UK and
overseas pathologists, provided they work or have
worked, at least occasionally, in the UK. In each circula-
tion there are 15 cases that are selected by the organizer on
the basis of the clinical history alone. It is advised that any
relevant clinical information existing when the original
report was dispatched is provided and that this material
should be made available to all participants. Each partici-
pant is given a numeric code, which is entered on the
return forms to permit a personal statistical analysis of
results. Reports giving the range and popularity of the
diagnoses are sent to all participants, along with the com-
ments and the original diagnoses. Histograms or other
statistical figures are used to give the distribution of the
accumulated scores for of each participant. This allows the
participant to see confidentially how his/her performance
compares with his/her peers. The computer program
which runs this system has been previously described
[10]. The program allows calculation of the degree of cor-
relation between the personal diagnosis and that formu-
lated by the consensus of the group. The numerical code
also permits anonymity and confidentiality and is known
only to a part-time secretary employed on the scheme.
There is an annual meeting at which cases are presented
and discussed and personal scores are calculated after the
suitability of each case for EQA purposes has been dis-
cussed at such a meeting. There is a definition of a "per-
sistent sub-standard performance" which is defined as any
participant whose score remains in the bottom 2.5% for
two circulations. Anonymity is broken if the chairman can
identify that standards of care are jeopardized. In the
event of a pathologist making diagnoses which are mark-
edly at variance with the consensus, the feedback system
should make that pathologist aware of the position. A bot-
tom line of 2.5% of participants has been proposed [11].
A number of procedures have also been proposed where
the Chairman of the Histopathology Advisory Panel will
be informed if he/she again scores in the bottom 2.5% of
the ranked order in two out of the next three circulations
[12]. It is advisable to start an investigation without break-
ing confidentiality, which seeks explanations rather than
taking punitive action. Such procedures have been
approved by the Council of the RCPath and are described
in more detail on the College website [13]. The organiza-
tion of the scheme requires the maintenance of a compu-
ter, postage, packing, and photocopying costs and a part-
time secretary. Thus, a number of positive aspects are
present in this scheme if compared with the other three
(Table 1). Concerning the evaluation of the BRIPPA EQA
as a revalidation method it should be indicated that such
a scheme has partial confidentiality, multiple sources of
data and assessors, and a sampling procedure over several
time frames, fulfilling almost all criteria necessary for a
revalidation method.
The EQA scheme of the Society of Pediatric Pathology
runs acceptably. In particular, the slide survey program of
the Society of Pediatric Pathology (USA) contains an
important educational component using three single
choice questions ("best of four") in addition to the field
"Your diagnosis". In this sense the credits gained by the
survey program are corroborated by active research of the
participant in the medical literature and the educational
value of the survey is perceptibly increased. Although the
use of a multiple choice question is a valuable and proba-
bly stimulating aspect of continuing medical education, it
remains of educational value, because it is so far from rou-
tine practice as to be irrelevant to EQA. A digital slide sur-
vey program has recently been started in late 2007, but a
full evaluation is lacking.
The slide box of the German Division of the International
Academy of Pathology allows pathologists working in a
German-speaking country to familiarize themselves with
pediatric pathology entities. A feedback form is included,
but it is not compulsory. A standard course (about once a
year) is offered explaining the diagnoses and differential
diagnoses as well as inserting additional comments or
molecular pathology notes. Digitalization of data is in
progress. At present four modules are offered for pediatric
pathologists and general pathologists with a significant
workload in pediatric pathology. No substandard per-
formance letter is issued.
The specialist module "Pediatric Pathology" of the Royal
College of Pathologists of Australasia, Section of Anatom-
ical Pathology, Quality Assurance Programme (RCPA AP
QAP) is accredited by the National Association of Testing
Authorities, Australia, and complies with the Require-
ments of ILAC G13 [14]. The 2007 survey was distributedBMC Clinical Pathology 2008, 8:11 http://www.biomedcentral.com/1472-6890/8/11
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to 75 participants in a range of Australian and interna-
tional laboratories: Australia 63%, New Zealand 12%,
Malaysia 12%, Other (Austria, Fiji, New Caledonia, Saudi
Arabia, Singapore, South Africa, Sweden, United Arab
Emirates) 13%. A major change for 2006 was the increase
of cases for each specialist module, now including a total
of ten slides per year. Initially slide sets and additional
digital files for virtual microscopy are provided. In 2005
the Royal College of Pathologists Australasia acquired the
Aperio ScanScope® system [15]. This system, which is in
addition to existing virtual microscopy equipment, was
funded under a Commonwealth government contract and
is fully operational at the RCPA QAP office. The virtual
microscopy equipment is able to scan diagnostic slides
and create digital images that can be magnified in a simi-
lar manner to light microscopy. The equipment contains
special features including a particular system of file com-
pression that allows highest resolution of histological
glass slides and the files are accessible through a free ware
viewing program for personal computers. In response to a
questionnaire sent to RCPA AP QAP participants, it was
found that about two thirds of participants were able to
download the software and open the digital files,
although only one out of two respondents had personal
access to a personal computer with the minimum require-
ments for viewing the scanned slides. About one third of
the participants upgraded a personal computer during the
following 12 months to establish all of the minimum
requirements and a further one third was able to upgrade
to all of the ideal requirements for viewing the images.
Three quarters of the respondents made a comment about
the use of virtual microscope images for EQA purposes. Of
these comments one third were positive, while the nega-
tive responses were mostly associated with the IT difficul-
ties found at workplace, such as firewalls or the lack of
DVD ROM drives. In the RCPA AP QAP module preferred
diagnoses can be submitted electronically (website) or by
fax or post. One of the most important achievements is
the acceptance of website submitting and interim results
are available on the RCPA AP QAP website immediately
Table 1: Factors used in the evaluation of histopathology EQA schemes
BRIPPA RCPA AP QAP SPP IAP-GD Comprehensive EQA6
No. of Circulations/year 21 3 1 2
No. slides/year 30 10 15 50 5 30
Membership Required1 Yes No Yes Yes Yes
Pediatric Pathology Required Yes No Yes No No
Open to Overseas participants Yes 3 Yes Yes Yes Yes
CPA accreditation 
(UK or similar accrediting bodies in other countries)
Yes Yes Yes Yes Yes
CPD/CME certificates Yes Yes Yes Yes Yes
CPD/CME credits 10 10 15 10 15
Slides Discussion Meeting Yes No No Yes Yes
Fixed Organizer Yes Yes Yes Yes Yes
Annual Report Issue Yes Yes Yes No Yes
Improvement/Changes Meeting Discussion Yes Yes 4 Yes No Yes
Digital Images option No Yes No No Yes
Substandard Performance Letter Yes No No No Yes
Minimum Levels of Participation Yes No No No Yes
Anonymous Responses2 Yes No No No Yes
Participant's option to reject EQA cases where inappropriate 
for the EQA requiring actually expert opinion
Yes Yes No No Yes
Participant's option to reject EQA cases due to lack of 
sufficient information
Yes Yes No No Yes
Participant's option to reject EQA cases due to poor staining 
quality
Yes Yes No No Yes
Notes: 1 The membership of the regulatory body (BRIPPA, RCPA, SPP, IAP) organizing the EQA is a requirement to participate in the 
histopathology survey; 2 the parameter 'anonymous responses' indicates that a coding is used to preserve the anonymity of the participants (It also 
means indirectly that explicit permission from the participant is required before data may be shared with local management, regional QA officers, 
accrediting bodies and suppliers of equipment and reagents); 3 with limitations (membership for pathologists is usually restricted to those with a 
regular commitment to work, usually locum work, in the United Kingdom); 4 with service online; 5 permanent set of stained sections (probably 
unsuitable for revalidation); 6 The comprehensive EQA is considered as major acceptance and author recommendation among the different EQAs. 
Neither EQA organizations nor the Medical University of Innsbruck are responsible for these conclusions.
BRIPPA: British Paediatric Pathology Association,
RCPA AP QAP: Royal College of Pathologists of Australasia Anatomical Pathology Quality Assurance Programme,
SPP: Society for Pediatric Pathology
IAP: International Academy of Pathology
CPA: Clinical Pathology Accreditation Ltd.BMC Clinical Pathology 2008, 8:11 http://www.biomedcentral.com/1472-6890/8/11
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after the closing date. Assessment criteria include five cat-
egories for the preferred diagnosis classified against the
target diagnosis. The diagnosis is classified concordant, if
the preferred diagnosis is essentially/substantially identi-
cal with the target diagnosis; minor discordant, if the pre-
ferred diagnosis has one or more minor differences from
the target diagnosis; discordant, if the preferred diagnosis
is substantially different from the target diagnosis, differ-
ential diagnoses only, if only a number of differential
diagnoses are reported, and unable to be assessed, if the
submission was late, illegible or unable to be interpreted,
including submissions in the form of a clinical report, a
fax instead of a web submission or those with no text in
the "preferred diagnosis" field. Participation as an individ-
ual in any of the diagnostic modules is recognized as a
CPD activity by the Board of Education of the Royal Col-
lege of Pathologists of Australasia.
If we consider all four programs together, we recommend
that an ideal quality assurance scheme should have, on
average, two circulations per year for a total of at least 30
slides per year, be addressed to pathologists with a sub-
stantial pediatric pathology workload, are accredited, pro-
vide CPD credits and certificates, and have regular slides
discussion meetings as well as scheme improvement
meetings, and lastly issue an annual report (Table 1).
Discussion
Clinical governance is one of the most frequent terms
encountered in health care management, in both the
national health services and private healthcare systems. It
describes a systematic approach maintaining and regu-
larly improving the quality of patient care while safe-
guarding high standards of care through creation of an
environment in which excellence in clinical care will
flourish. The elements of clinical governance advance
health care professional education, clinical audit, clinical
effectiveness, risk management, good professional prac-
tice-based research and development, confidential-based
honesty procedures. In this study, we delineate the charac-
teristics of an EQA scheme that should be taken into con-
sideration when establishing a national or local EQA
scheme. We consider that if a quality assurance scheme is
to be suitable as revalidation method it should have two
circulations per year, requirement for membership or a
substantial pediatric pathology workload. It should be
open to overseas participants, have CPA accreditation,
provide CPD credits and certificates, and have regular
slides discussion and scheme improvement meetings and
an annual report. Internal audits and a 'black box' of tis-
sue slides are important, but external proficiency testing is
advocated as an independent means for continuing pro-
fessional development and to support laboratory accredi-
tation. Indeed, laboratory services are a central core in the
diagnostic procedures of a general hospital [16]. The
"Pediatric Pathology" module of slide survey programs is
targeted for pediatric pathologists, general pathologists
who have pediatric cases in their diagnostic routine, pedi-
atric pathology fellows and pathology residents.
The concept of EQA programs relies on the fact that par-
ticipants should view cases without consulting colleagues
before submission to the program office. Uniformity of
standards to set up a quality assurance program at
national level is an important task. The use of physician
specialization to assess the quality of care provided by
individual physicians represents a structural approach to
measuring quality. In the last 10 years there has been an
enormous change in revalidation in the United States.
This is because physician specialization as represented by
board certification may be an unreliable measure of the
quality of a physician's performance over time, unless his
or her knowledge and skills in a specialty area are period-
ically updated or assessed.
In such a way, there is no guarantee that physicians have
maintained the same level of skills and knowledge they
demonstrated for their initial certification without a
revalidation process. Thus, the search for a practicable
revalidation method is very valuable. According to our
data and considerations, the UK scheme has an educa-
tional component largely as a by-product of participation,
but it can easily be used as a form for medical revalida-
tion. This is because it possesses a partial confidentiality,
contains multiple sources of data and assessors, and has a
sampling procedure over several time frames rather than
at a single point. The German scheme would appear to be
essentially that of an educational program and possibly
the North American scheme too. The Australian scheme
seems to have both educational and revalidation compo-
nents, but the number of slides is low and there is only
one circulation per year that we consider insufficient as a
revalidation method.
In assessing EQA schemes one aspect that has to be
emphasized is the 'consensus answer'. The EQA utilizes
the consensus answer as the correct answer which may not
necessarily be the same as an 'expert' answer. Inter-
observer reliability (consistency) may be reassuring, but
there is a risk of a group response that can become very
unpredictable. [17] The participants may all agree, but the
correct or best answer may not be made as all of the par-
ticipants are wrong. Similarly, an expert opinion is not
necessarily correct. It is well recognized in pathology that
there are instances when pathologists cannot agree as to
the correct answer even on cases that are not unusual or
rarities. Disagreement between experts is to be expected
and should not necessarily give rise to concern over their
competence [18]. Consequently, the EQA, rather than
measuring expertise, is measuring a minimum commonBMC Clinical Pathology 2008, 8:11 http://www.biomedcentral.com/1472-6890/8/11
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level of attainment (i.e. conformity to consensus). There-
fore how the consensus should be assessed? There are sev-
eral forms of consensus used today. The promise of
achieving a consensus creates the impression that one
group may be able to operate without conflict. Consensus'
philosophy fosters an atmosphere that encourages the
expression of different opinions and even conflict, and
then provides a process that may lead to a resolution in a
creative and very supportive environment. It recognizes
that everyone has a contribution to make, and that all
views are encouraged, but it may take several meetings to
work towards a decision and at the end of the process it is
not uncommon for some people to continue to disagree
with the final decision. The Delphi Technique and Nomi-
nal Group Technique are two well-recognized consensus-
formation methodologies specifically designed to com-
bine judgments from a group of experts [19,20]. The Del-
phi Technique utilizes a series of well-defined
questionnaire-based surveys, whereas Nominal Group
Technique is a structured face-to-face meeting designed to
facilitate consensus. Consensus-formation techniques
require that each step builds on the results of the previous
steps. In the majority of the EQA survey programs for
pathologists the correct diagnosis is not indicated as
'expert judgment' but conversely a 'democratic' consensus
is sought by judgment of the majority of participants and
discussion in the case of conflicting results. In some situ-
ations, a consensus cannot be reached and the controver-
sial tissue slide is excluded from the final EQA
performance. The rejection of cases not reaching 80%
agreement between participants can be criticized, as it is
artificial, but it is a compromise [21]. As a consequence of
rejecting such cases, the distribution of the score profile
becomes skewed.
Another aspect at the base of some controversial issues in
EQA in pathology may be the lack of uniform guidelines
that are valid worldwide. Thus, our study first tries to com-
pare four international survey programs, emphasizing the
need for harmonization. However, lack of harmonization
also relies on the different interpretation of some pathol-
ogy. An example is the diagnosis of chronic intestinal
pseudo-obstruction in children. The diagnosis of intesti-
nal neuronal dysplasia as an isolated entity is indeed very
controversial. Intestinal neuronal dysplasia is character-
ized by hyperplasia of the submucosal and myenteric
plexuses and the isolated form has been described in the
distal colon and rectum, and its clinical presentation, with
constipation and intestinal obstruction, can mimic that of
Hirschsprung disease or aganglionosis [22,23]. During
the years since the entity was first described, the criteria
have also been modified. However, in many countries,
mostly of Anglo-Saxon origin, the current view is that iso-
lated intestinal neuronal dysplasia is seen in a variety of
clinical settings and is more a descriptive entity than a spe-
cific disease requiring surgical intervention [24].
It is difficult to identify the minimal number of slides that
needs to be assessed for consideration as a revalidation
method. We initially considered the number of cases of
pediatric and placental pathology in a tertiary academic
center. The number of cases of pediatric and placental
pathology was found to be approximately 1500 in many
institutions (personal communication) over the years.
Subsequently, we considered the percentage of 'permitted
wrong diagnoses' in the diagnostic routine identified in
the English literature. The results of studies concerned
with error rates in histopathology vary widely; no serious
errors, [25] 0.26%, [26] up to 1.2% of histopathological
reports [27]) but these were performed in academic or
teaching institutions. In reality, the percentage is quite
variable when considering sub-specialistic, inter-individ-
ual and intra-individual variability studies [28]. It has also
been suggested in the USA that false negative rates of 5–
10% may be an admirable goal in cytopathology, and
rates below 15–20% are a possible standard [29]. We
allowed 2% in consideration of typographical errors, and
hypothesized that a valuable number of EQA diagnoses
could be 30 (2% of 1500 diagnoses), keeping in mind an
artificial assumption that the highest number of wrong
diagnoses can be equivalent to the number of histological
glass slides that run in a annual EQA program. Thus, we
propose that 30 should be the minimal number of slides
per year assessed in an EQA program by a specialist pedi-
atric pathologist. In this sense, the UK scheme with 30
slides per year might be considered as a standard and may
serve better as a revalidation method.
Health services are awash with data, but safety is a cate-
gory that needs to be continuously improved for health
services. IT resources appear to be the greatest barrier to
obtaining access to virtual images. This can be overcome
if hospitals or government upgrade workstations to have
compatible IT systems and allow access for quality assur-
ance purposes. Smooth running quality assurance pro-
grams can improve this relationship and strengthen the
link with the clinicians. Modernizing the pathology labo-
ratory commences with virtual microscopy and services
will provide a remarkable wealth for the child's growth in
the 3rd millennium. Image digitalization is a new tool to
use for biopsy specimens that cannot be cut in 40–60
slides for all participants. Indubitably, digital imaging
with virtual microscopy will be more closely linked to
practice in the future. To date, glass slides mimic the rou-
tine practice worldwide. Thus, digital images for EQA are
a compromise offering the possibility to extend the range
of cases to include small specimens, such as endoscopic
and fine needle biopsies. Another possibility is to manage
the use of glass slides from small biopsies through a postalBMC Clinical Pathology 2008, 8:11 http://www.biomedcentral.com/1472-6890/8/11
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system, circulating slides sequentially between partici-
pants. In the recent UKNEQAS Meeting in Glasgow it was
stated that the EQA remains an extremely valuable
resource for clinical pathologists and needs a well-organ-
ized, rapid and manageable system to run efficiently [31].
It seems evident that EQA drives standardization and
there are many examples supporting this fact, including
those where peer-driven changes are influenced by EQA
findings [31]. One aspect that was not considered in this
study was the difficulty of the histological glass slides uti-
lized in the circulations. However, in our opinion, there
was no significant disparity in the difficulty of diagnosis
because some recommendations have been proposed and
followed in all four EQA schemes examined. In particular,
the diagnosis should be made using the hematoxylin and
eosin stained slide and no immunohistochemistry should
be needed to arrive to the diagnosis. Lymph node cases
usually represent a frequent source of difficulty and spe-
cific details have to be provided in submitting such cases.
Thus, the method for selecting cases has a crucial impact
on whether the cases are more difficult (and hence more
educational) or more representative of the routine work-
load (and therefore more relevant to performance surveil-
lance). Cases should be contributed by all participants in
rotation, following agreed guidelines. Extremely 'simple'
cases should be avoided, to be determined at meetings of
the participants, but bizarre cases and case-report material
remain inappropriate. The number of cases circulated
must be sufficient to give reasonable confidence that seri-
ous sub-standard performance will be promptly identi-
fied.
Inappropriate tissue slides, limited number of circula-
tions, lack of secretarial support, and low number of par-
ticipants may jeopardize the EQA as a revalidation
method. The importance is to establish a quality manage-
ment system, allocate privileged time for it and ensure a
reasonable cost load for healthcare organizations. It is
important to specify well defined implications for
schemes and participants. Further, we believe that a peri-
odically reviewed and updated quality policies manual in
addition to continuing audit of performance should be
standard in every histopathology department. The associ-
ation with a CPA accredited laboratory (contractual agree-
ment) should be considered. If an EQA scheme is not run
in a department, it is recommended that the department
is not given accreditation.
Business and healthcare organizations regularly use the
process of benchmarking to learn how others address pol-
icy issues and solve problems. The improvement of diag-
nostic skills in pathology is of paramount importance and
the interest in programs that provide external proficiency
testing, quality assessment and appropriate education
programs to public and private laboratories of pathology
and laboratory medicine is growing rapidly. There are
some associations and companies supplying both quality
assurance programs and supporting services for the bene-
fit of pathology laboratories and personnel working
within the pathology environment. The substantial
advantage of internal audit and slide survey is intrinsically
present in these programs intended to continually
improve pathology services for the well being of commu-
nities. There is no direct evidence to support the validity
of histopathology EQA, but there are various strands of
indirect evidence that can be drawn together to underpin
validity. Indirect evidence to support validity includes the
response process used in the EQA. This reflects actual
working practice undertaken by pathologists. EQA started
originally as a 'hobby' for pathologist participants, but
now it has acquired or is acquiring a central role as part of
continuing professional development. It may be used as a
revalidation method, because it represents clear of medi-
cal qualification, its' results may be given to the public, it
may contain multiple sources of data and assessors and it
represents a sampling procedure over several time frames
rather than at a single point. However, the purposes and
programs of EQA schemes can be different worldwide and
in consideration of its possible use as revalidation
method, it is strongly advisable that all EQA programs are
unified as soon as possible.
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